newsfilter
← Interviews
a16z39 min

Inside Moderna’s Biggest mRNA Test Since COVID

Jorge Conde, Stéphane Bancel

Interview, Fireside Chat

Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismoran, successfully met primary and secondary endpoints in a Phase 3 melanoma trial, demonstrating superior recurrence-free survival compared to the current standard of care. This breakthrough treatment combines a patient-specific mRNA vaccine with Merck's Keytruda to target unique tumor antigens, offering a synthetic manufacturing solution that can produce individualized doses within approximately 42 days. Building on these results, the companies plan to file for FDA approval with the goal of patient availability by 2027 while expanding clinical trials to lung, kidney, and bladder cancers.